

Impaired Activated/Memory Regulatory T Cell Clonal Expansion Instigates Diabetes in NOD Mice

Vanessa Mhanna, Gwladys Fourcade, Pierre Barennes, Valentin Quiniou, Hang P Pham, Paul-Gydeon Ritvo, Faustine Brimaud, Bruno Gouritin, Guillaume Churlaud, Adrien Six, et al.

▶ To cite this version:

Vanessa Mhanna, Gwladys Fourcade, Pierre Barennes, Valentin Quiniou, Hang P Pham, et al.. Impaired Activated/Memory Regulatory T Cell Clonal Expansion Instigates Diabetes in NOD Mice. Diabetes, 2021, 70 (4), pp.976-985. 10.2337/db20-0896 . hal-03263428

HAL Id: hal-03263428 https://hal.sorbonne-universite.fr/hal-03263428

Submitted on 17 Jun2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. Impaired activated/memory regulatory T cell clonal expansion instigates
 diabetes in NOD mice

- 3
- 4 Vanessa Mhanna^a, Gwladys Fourcade^a, Pierre Barennes^a, Valentin Quiniou^{a,b}, Hang P.
- 5 Pham^c, Paul-Gydeon Ritvo^a, Faustine Brimaud^a, Bruno Gouritin^a, Guillaume Churlaud^{a,b},
- 6 Adrien Six^{a,1}, Encarnita Mariotti-Ferrandiz^{a,1}, David Klatzmann^{a,b,1*}
- 7
- ⁸ ^aSorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3),
- 9 F-75005 Paris, France.
- 10 ^bAP-HP, Hôpital Pitié-Salpêtrière, Biotherapy (CIC-BTi) and
- 11 Inflammation-Immunopathology-Biotherapy Department (i2B), F-75013, Paris, France.
- 12 ^cILTOO Pharma, Statistics Department, Paris, France.
- 13 ¹co-senior authors
- 14 *corresponding author
- 15 Email: david.klatzmann@sorbonne-universite.fr
- 16 **Phone number: +33 1 42 17 74 60**
- 17
- 18 Word count: 3994
- 19 Number of figures: 5
- 20 Keywords
- 21 Tolerance, immune regulation, immunopathology, immunotherapy, systems biology

23 Abstract

24 Regulatory T cell (Treg) insufficiency licenses the destruction of insulin-producing 25 pancreatic β cells by auto-reactive effector T cells (Teffs), causing spontaneous 26 autoimmune diabetes in non-obese diabetic (NOD) mice. We investigated the 27 contribution to diabetes of the TCR repertoires of naive regulatory T cells (nTregs), activated/memory Tregs (amTregs), and CD4⁺ Teffs from prediabetic NOD mice and 28 29 normal C57BL/6 (B6) mice. NOD mice amTreg and Teff repertoire diversity was 30 unexpectedly higher than that of B6 mice. This was due to the presence of highly 31 expanded clonotypes in B6 amTregs and Teffs that were largely lost in their NOD 32 counterparts. IL-2 administration to NOD mice restored such amTreg clonotype 33 expansions and prevented diabetes development. In contrast, IL-2 administration only led 34 to few or no clonotype expansions in nTregs and Teffs, respectively. Noteworthily, IL-2 35 expanded amTreg and nTreg clonotypes were markedly enriched in islet-antigen specific 36 TCRs. Altogether, our results highlight the link between a reduced clonotype expansion 37 within the activated Treg repertoire and the development of an autoimmune disease. They 38 also indicate that the repertoire of amTregs is amenable to rejuvenation by IL-2.

39 Non-obese diabetic (NOD) mice spontaneously develop autoimmune diabetes due to the 40 destruction of insulin-producing β cells by auto-reactive CD4+ and CD8+ T cells (1). 41 Diabetes susceptibility in NOD mice is attributed to genetic defects encoded by the 42 insulin-dependent diabetes (idd) loci including over 40 genes, among which the MHC 43 class II and interleukin-2 (IL-2) genes have major contributions to the pathophysiological immune response leading to diabetes (2). The unique I-A^{g7} MHC-II molecule expressed 44 45 by NOD mice has been reported to bind certain peptides with low affinity, thus impairing 46 the thymocyte negative selection process (3,4). Reduced IL-2 production by activated 47 effector T cells (Teffs) was found in NOD mice and linked to an impairment of Treg 48 numbers and functionality (5-7). An increased diabetes incidence was observed in NOD 49 mice bearing an IL-2 alpha receptor subunit with reduced affinity for IL-2, which was 50 associated with a Treg but not a Teff defect (8). Likewise, the administration of low-dose 51 IL-2 to NOD mice promotes Treg expansion and activation, prevents diabetes onset and 52 even cures diabetic mice (9, 10). Thus, the altered tolerance promoting diabetes in NOD 53 mice could be the result of (i) a defect in thymic selection of Treg and Teff T-cell 54 receptor (TCR) repertoires and/or (ii) an altered Treg fitness due to IL-2 deprivation. 55 Previous studies of the TCR repertoires of NOD mice and type 1 diabetes patients yielded 56 inconsistent results. Some studies showed a restricted TRBV and TRBJ chain usage by 57 CD4⁺ T cells from pancreatic islets and pancreatic lymph nodes (PLN), indicating that 58 overrepresented islet-specific TCRs preferentially express certain TRBVJ genes (11-13). 59 Conversely, others showed a rather diverse gene usage among islet-infiltrating CD4⁺ T 60 cells in NOD mice (14), including islet-infiltrating memory $CD4^+T$ cells (15, 16), and no 61 common highly used TRBVBJ combinations in T cells from PLN of type 1 diabetes

patients (17). Moreover, NOD Tregs were found to have a restricted TRA repertoire and 62 63 limited overlap with thymic CD4⁺ T cells (18, 19), while we found similar TRB diversity between NOD peripheral Tregs and Teffs (20). These somehow conflicting results can be 64 65 explained by the fact that (i) most of these studies were performed on unsorted $CD4^+ T$ 66 cells and thus did not distinguish between regulatory and effector populations and/or (ii) 67 most Treg repertoire analyses were done on a limited fraction of the repertoire by using 68 TCR transgenic NOD mice or by focusing on few rearrangements (18, 19). More 69 importantly, most studies have overlooked the existence of regulatory T cell subsets.

70 Indeed, we previously showed that Tregs could be phenotypically divided into CD4⁺Foxp3⁺CD44^{low} CD62L^{high} naïve Tregs (nTregs) that have a low turnover, and 71 CD4⁺Foxp3⁺CD44^{high}CD62L^{low} activated/memory Tregs (amTregs) that have a very 72 73 rapid turnover due to their interaction with their cognate antigens (21). In the healthy B6 74 mouse background, we showed that amTregs are enriched in deep tissue-draining lymph 75 nodes (LNs) and are characterized by unique clonotype expansions (22). Moreover, we 76 showed little overlap between amTreg and nTreg TRB repertoires (22). Thus, studying 77 amTreg and nTreg TCR repertoires without separating them may be confounding.

Here we compared the TCR repertoire of splenic amTregs, nTregs and Teffs of prediabetic NOD and normal B6 mice to investigate whether and how an altered TCR repertoire contributes to diabetes. We found that NOD amTregs have an unexpectedly more diverse repertoire than that of B6 mice, due to the absence of expanded clonotypes. Treatment of prediabetic NOD mice with IL-2, which prevents diabetes occurrence, restored the expansion of clonotypes that are preferentially diabetes-reactive. Thus, the 84 TCR repertoire of amTregs is altered by an IL-2 insufficiency, which instigates diabetes
85 development in NOD mice, and is amenable to therapeutic recovery.

86 **Research Design and Methods**

87 Study design

Given the rarity of some of the studied cell subsets, we pooled the spleens of 6 to 8 young mice matched for genetic background, age and sex. Six (three female and three male) non-treated C57BL/6 or NOD pools of mice were used to study the repertoire at homeostasis. Six young female NOD mice were treated with IL-2. Sample size was determined for statistical significance and experimental feasibility. Investigators were not blinded to the allocations during experiments and analyses.

94 **Mice**

95 Eight- to ten-week-old male and female C57BL/6- and NOD-Foxp3-EGFP transgenic 96 mice expressing green fluorescent protein (GFP) under the control of the Foxp3 gene 97 promoter were respectively provided by B. Malissen (Luminy, Marseille) and V. 98 Kuchroo (Brigham and Women's Hospital, Boston, MA). All animals were maintained at 99 the Sorbonne Université Centre d'Expérimentation Fonctionnelle animal facility under 100 specific pathogen-free conditions in agreement with the current European legislation on 101 animal care, housing and scientific experimentation (agreement number A751315). All 102 procedures were approved by the local animal ethics committee.

103 IL-2 treatment

104 Recombinant AAV8 vectors were produced as described previously (9). Six female 105 NOD-Foxp3-EGFP mice were injected once intraperitoneally with 10¹¹ of rAAVs diluted 106 in PBS at 6 weeks of age. Serum was collected two weeks post-injection and IL-2 levels 107 were measured using a mouse IL-2 ELISA (eBioscience) according to the manufacturer's 108 recommendations. Mice were sacrificed at nine weeks of age.

109 Spleen retrieval and cell sorting

110 Spleens were collected from euthanized mice and splenocytes were stained with anti-Ter-111 (BD Biosciences), -B220-biotin (eBioscience) and -CD11c-biotin 119-biotin 112 (eBioscience) antibodies for 20 min at 4°C and labeled with anti-biotin magnetic beads (Miltenyi Biotec) for 15 min at 4°C. B cells, erythrocytes and monocytes were depleted 113 114 on an AutoMACS separator (Miltenyi Biotec) following the manufacturer's procedure. 115 Enriched T cells were stained for 20 min at 4°C with the following monoclonal 116 antibodies at predetermined optimal dilutions: CD3-APC (BD Biosciences), CD4-117 Horizon-V500 (BD Biosciences), CD8-Alexa-700 (BD Biosciences), CD44-PE (BD 118 Biosciences) and CD62L-eFluor-450 (eBioscience) and sorted on a FACSAria II 119 cytometer (BD Biosciences) with a purity > 95% into the following subsets: $CD4^+$ FoxP3⁺ CD62^{low} CD44^{high} (activated/memory Tregs (amTregs)), CD4⁺ FoxP3⁺ CD62^{high} 120 CD44^{low} (naive Tregs (nTregs)) and CD4⁺ FoxP3⁻ (T effector cells (Teffs)). 1.10⁵ to 5.10⁶ 121 122 sorted cells were stored in RNAqueous kit lysis buffer (Invitrogen) at -80 °C.

123 cDNA library preparation for TR sequencing

124 RNA was extracted using the RNAqueous Total RNA Isolation Kit (Invitrogen). TRB

125 libraries were prepared on 100 ng of RNA with the SMARTer Mouse TCRa/b Profiling

- 126 Kit (Takarabio) and sequenced with HiSeq 2500 single read (300 bp) (Illumina) + 10%
- 127 PhiX at the "LIGAN Genomics platform" (23).
- 128 Raw read processing

Raw data in FASTQ format were processed for TRB sequence annotation using MiXCR software (v.3.0.3) (24), which ensures PCR and sequencing error corrections and provides for each sample a list of unique amino acid TRBs and their corresponding counts. Annotated sequences were then analyzed using an in-house workflow to eliminate long amino acid CDR3 sequences (length higher than the mean + 8). The resulting datasets are summarized in Table S2.

135 Data analysis

136 Statistical comparison

Sample overlap was tested by computing the Jaccard distance (25) using the "vegan" R package and plotted into a heatmap using the "pheatmap" package (26). Clustering analysis was performed using the 'Ward' method. Principal component analysis was performed using the "stats" R package. Renyi entropy (27) was calculated using "vegan" and represents the distribution of clonal expansions as a function of the parameter *alpha*. Probability density plots were plotted using the "ggplot2" R package (28).

143 Network analysis

For each cell population, the following method was adopted: The top most frequent 1000CDR3 amino acid sequences from each of the six B6 or NOD mice were pooled and the

146 mean frequency was calculated for every sequence. The list was then ordered 147 decreasingly and the first 1000 sequences were selected. A matrix of pairwise 148 Levenshtein distances (LD) between the CDR3s was computed and used to construct the 149 networks. In these networks, vertices (CDR3 sequences) are connected by edges (LD=1) 150 only if they differ by one amino acid (insertion/deletion/substitution). A connected cluster 151 is defined as a set of two or more vertices connected by edges. The clustering coefficient 152 of a node in a network quantifies how close its neighbors are to being a clique (a closed 153 cluster). The maximum value is 1 if every neighbor connected to the node A is also 154 connected to every other node within the neighborhood. The node size represents the 155 mean frequency of each CDR3 in the network.

Analyses were performed using R packages: "stringdist" (29) was used to calculate LDs
and "Igraph" (30) to calculate network properties. Graphics visualization were done using
Cytoscape (31) and "ggplot2" for figures 3 and 5 respectively. In the latter, only clustered
nodes are represented and edges are not shown.

160 Identification of expanded clonotypes

In each sample, the first (Q1) and third (Q3) quartiles and the interquartile range (IQR) were computed according to a negative binomial distribution fitted in the sequence read counts, while excluding private clonotypes with a count of 1. Expanded clonotypes are defined as those with counts greater than $Q3 + 1.5 \times IQR$.

165 TCR Database

Mouse CDR3 β s associated with diabetes (n=52), EAE (n=50), SLE (n=49) and cancer (n=52) were collected from Friedman's published database (*32*). These sequences were derived from CD4⁺ T cells and identified by different methods including reactivity assays, tetramer staining, selection of diabetes-specific TCRs following diabetesinduction and by sequencing of tumor T cell infiltrates in the context of cancer studies.

171 Statistical analyses

172 Statistical analyses were performed using the nonparametric Wilcoxon test with Holm

173 multiple testing correction using "ggpubr" R package (33). A p value of ≤ 0.05 was

174 considered statistically significant; * $p \le 0.05$, ** $p \le 0.01$, *** $p \le 0.001$, **** $p \le 0.0001$

and n.s. denotes not significant (p > 0.05). Mean percentage comparisons of diabetes,

176 EAE, SLE and cancer CDR3s were done using the Wilcoxon paired test with diabetes as

177 a reference group.

178 Data availability

Source data are provided in the manuscript and the Supplementary materials. Fastq data
were deposited in NCBI Sequence Read Archive repository under the BioProject ID
PRJNA635928.

182 **Results**

183 Differences in repertoire composition between B6 and NOD

We analyzed and compared the TCR beta chain (TRB) repertoire of splenic CD4⁺Foxp3⁺CD44^{low}CD62L^{high} nTregs, CD4⁺Foxp3⁺CD44^{high} CD62L^{low} amTregs and

186 Foxp3⁻CD4⁺ Teffs in B6 and NOD mice.

187 Compared to B6 mice, flow cytometry showed a significant decrease in the NOD Treg 188 population ($p \le 0.05$) associated with a decrease of amTreg proportions ($p \le 0.01$) (Table 189 S 1). Cell numbers for each sorted population and their corresponding number of TRB 190 sequences and unique amino acid clonotypes are summarized in Table S2.

191 Principal component analysis of TRBVBJ usage, i.e. the frequency of each combination 192 in the repertoire irrespective of the clonotype abundance, clearly separated the genetic 193 backgrounds and the cell populations (Figure 1A). The first two components showed 194 different TRBVBJ usage between B6 and NOD mice, with the first component (PC1) that 195 separates the two genetic backgrounds explaining more than 68% of the variability. There 196 was also a clear difference between the cell populations from the same background, with 197 the two Treg subsets being close, but quite apart from Teffs. This reflects differences in 198 the combined generation frequency and survival through the thymic selection and 199 peripheral expansion of each generated TRBVBJ recombination.

To further investigate these differences, we assessed the clonotype (i.e. unique amino acid TRBV-CDR3-TRBJ sequence) overlap between samples using the Jaccard distance in which the higher the value, the more dissimilar the pair of samples compared (Figure 1B). Hierarchical clustering on the Jaccard scores accurately separated B6 from NOD mouse samples. Surprisingly, within the latter cluster, amTregs are intermingled with nTregs and Teffs, while, as expected from our previous study (*22*), amTregs clustered separately in the B6 background. Overall, NOD mice display a peculiar repertoirestructure compared to B6 mice both at the TRB gene and clonotype level.

208 Increased TCR diversity of Teffs and amTregs in NOD versus B6 mice

We next explored the overall repertoire diversity at the clonotype level. We compared cell populations and mouse backgrounds by calculating the Renyi entropy, which evaluates diversity as a function of an *alpha* parameter (Figure 2A). The higher the *alpha*, the higher is the weight put on frequent clonotypes. The higher the Renyi entropy, the more diverse is the repertoire.

214 In B6 mice, nTregs have the most diverse repertoire while amTregs have the least diverse 215 one, and Teffs fall in between. In contrast, while nTregs in NOD mice have a repertoire 216 with a diversity similar to that in B6 mice, the diversities of the Teff and amTreg 217 repertoires are increased compared to B6 mice (Figure 2A). At *alpha=0*, for which the 218 Renyi index represents clonotype richness, no differences were observed between the B6 219 and NOD backgrounds (Figure 2B, left). This indicates that the overall richness of each cell subset is not affected in NOD mice. At alpha=8, which gives more weight to 220 221 abundant clonotypes, Renyi indices were significantly higher in NOD amTregs and Teffs 222 than in the corresponding subsets in B6 mice (Figure 2B, right).

In view of these differences, we looked at the representativeness of the 100 most predominant clonotypes within each repertoire. The cumulative percentages of the 100 most predominant clonotypes in B6 amTregs and Teffs were significantly higher than their NOD counterparts (Figure 2C). This is due to the presence, in the B6 cell populations, of highly frequent clonotypes depicted by blue lines which thickness is proportional to their percentage in the repertoire (Figure 2D). In contrast, there were no such clonotypes in B6 nor in NOD nTregs.

Collectively, these results reveal that a healthy naïve Treg repertoire is diverse with no clonotype expansions. Conversely, the healthy amTreg repertoire, and to a lesser extent the Teff repertoire, are enriched in clonotypes with high frequency, likely resulting from antigen-driven expansions. In diabetes-prone NOD mice, such expansions are severely reduced in amTregs and Teffs.

235 Altered similarity structure of NOD amTreg and Teff repertoires

Next, we examined the architecture of the repertoires. To this end, the 1000 most frequent CDR3s per population were used to build similarity networks in which each CDR3 (node) has a size proportional to its frequency and is connected by edges to other CDR3s that differ to it by only one amino acid, i.e. having a Levenshtein distance of 1 (LD=1). This distance was shown to connect CDR3s that are likely to bind the same peptide (*34*).

The structure of the nTreg repertoire appeared similar for B6 and NOD mice, made of highly clustered CDR3s with low frequency (Figure 3A). In contrast, B6 amTreg repertoire was mostly composed of individual or lightly connected with high frequencies, reflecting polyclonal self-antigen-driven expansions (*22,35*). In accordance with the previous observations (Figures 1 and 2), these expansions are much reduced in amTregs from NOD mice. Similarly, node sizes of their Teffs appeared smaller than in B6 mice (Figure 3A, middle).

Node frequency showed no differences for nTregs, a modest decrease for Teffs and a marked decrease for amTregs in NOD mice compared to their counterparts in B6 mice (Figure 3B). The clustering coefficient of each CDR3 within each network, which gives an indication of the importance of these nodes in the global repertoire architecture, showed no significant difference between NOD and B6 nTregs (Figure 3C). However, significantly higher clustering coefficients were observed in Teffs and amTregs fromNOD compared to B6 mice.

Overall, the structural analysis of these networks highlights a higher sequence similarity

of Teff and amTreg CDR3s in NOD mice. As IL-2 production is notoriously low in NOD

mice and Tregs rely primarily on it for proliferation, we hypothesized that the reduced

260 Low dose IL-2 normalizes NOD amTreg repertoires

amTreg expansions may result from an IL-2 shortage.

256

257

258

259

261 As administration of IL-2 to NOD mice specifically enables the expansion of Tregs (9), 262 we-investigated whether the abnormal repertoire diversity and structure of prediabetic 263 NOD mice could be restored by an IL-2 treatment. NOD mice were injected with an adeno-associated virus coding for IL-2 (AAV-IL-2) that allows the continuous production 264 265 of IL-2 at low dose and prevents the occurrence of diabetes (9). As expected, total Treg 266 proportions increased significantly after IL-2 treatment (Figure 4A). Importantly, within 267 the Treg subsets, amTreg proportions showed a significant increase, at the expense of 268 nTregs (Figure 4A, Table S 3).

269 We next analyzed the expansions at the clonotype level after IL-2 treatment. To this end, 270 we identified expanded clonotypes as the ones showing counts greater than the 271 $Q3 + 1.5 \times IQR$ value, where Q3 is the third quartile and IQR the interquartile range of 272 sequence count distribution (see the Methods section and Table S 4). The abundance of 273 the expanded clonotypes from each sample was plotted in Figure 4B (left plots). Each 274 circle represents a clonotype whose size is proportional to its frequency in the repertoire. 275 amTregs and nTregs from AAV-IL-2-treated NOD mice were significantly enriched in 276 expansions compared to amTregs and nTregs from B6 or NOD mice. This is confirmed 277 by the density plots, which show that IL-2 treatment induces expansions of nTregs and amTregs compared to their B6 and NOD counterparts, but not of Teffs (Figure 4B, right
plot). Thus, IL-2 administration restores amTreg clonotype expansions that were absent
in NOD mice.

281 IL-2-expanded Tregs are enriched in diabetes-specific clonotypes

282 We next examined whether the expanded clonotypes could be linked to diabetes. We 283 queried a published catalogue of TCRs with defined specificity (32). We identified a total 284 of 203 mouse CDR3B amino acid sequences from CD4+ T cells associated with diabetes 285 (n=52), experimental autoimmune encephalomyelitis (EAE; n=50), systemic lupus 286 erythematosus (SLE; n=49) and cancer (n=52). We then searched for these sequences 287 within the expanded clonotypes and calculated their mean enrichment in each cell subset 288 (Figure 5A). Interestingly, diabetes-specific sequences showed higher expansions 289 compared to non-diabetes-specific sequences in nTregs and amTregs from IL-2-treated 290 NOD mice. There was also a modest enrichment of these sequences in B6 amTregs. To 291 further analyze the specificity pattern towards diabetes, we connected disease-specific 292 CDR3s by LD=1 to the pool of expanded amTreg and nTreg CDR3s. The number of 293 neighbors with LD=1 to diabetes-related sequences showed a significant increase 294 compared to other disease-specific CDR3s (Figure 5B).

Noteworthily, clonotypes identified as specific for islet antigens such as insulin and
glutamic acid decarboxylase by tetramer staining were detected in large clusters of IL-2
expanded clonotypes (Figure 5C, and Table S5).

298 **Discussion**

In this study, we report an altered amTreg TCR repertoire in NOD mice that can be restored to normal by an IL-2 treatment. IL-2 expanded Tregs were enriched in

islet-antigen-specific TCRs and were associated with protection from diabetes. Theseresults have both heuristic and applied implications.

303 The structure of the am- and n-Treg repertoires in a healthy mouse background

304 In normal B6 mice, a control model that do not spontaneously develop any inflammatory 305 or autoimmune diseases, nTreg repertoires are very diverse, even more than those of 306 Teffs, with most clonotypes forming dense networks. These are the attributes of an 307 unmodified and tightly connected post-thymic selection repertoire (36). In contrast, 308 amTreg repertoires have a reduced diversity and are enriched in frequent clonotypes with 309 few connections. This illustrates the responses to distinct self-antigens, as expected from 310 a cell population that is constantly activated to control autoimmunity in numerous tissues. 311 Such similarity structures have also been described in the context of immunization and 312 aging (34).

In addition, amTreg repertoires show a higher overlap with each other than with nTregs or Teffs, indicating that the self-antigens to which amTregs respond are shared between individuals. This is also in agreement with our previous report of a low sequence overlap between the two Treg subsets in the peripheral lymph nodes (*22*). The comparison with Treg TRB repertoires from the NOD autoimmune-prone mouse strain strengthens this conclusion. Reduction of amTreg major expansions is associated with disease susceptibility, and their recovery with disease prevention.

320 Collectively, these results identify amTregs as the major subset involved in the 321 pathogenesis of autoimmunity and warrant separate analysis of amTregs and nTregs 322 when investigating their roles in health or disease.

323 amTreg activation depends on IL-2

The severe reduction in frequent clonotypes found in NOD mice, and their appearance under IL-2 provision, highlight a major role of IL-2 in supporting amTreg survival.

326 NOD mice have a genetically determined IL-2 insufficiency, which is also reported in 327 human type 1 diabetes as well as in SLE and rheumatoid arthritis (37, 38). It is thus likely 328 that the observed defect in amTreg fitness contributes to the pathophysiology of these 329 diseases. If so, the good news is that disease-relevant amTregs, can be regenerated by IL-330 2 treatment. We show herein that one injection of rAAV-IL-2 in prediabetic mice was 331 enough to expand NOD amTregs at the cell and repertoire levels. In our experiments, the 332 repertoire was analyzed 21 days after the initiation of treatment. As the approximate 333 duration of T cell differentiation in the thymus is of 28 days (39), newly generated 334 thymocytes are unlikely to contribute to the expanded clonotypes in the amTreg 335 population. Thus, the IL-2-induced amTregs most probably originate from peripheral 336 amTregs and/or nTregs that received their activation signal in the presence of IL-2. The 337 diabetes-related TCR expansions in both nTregs and amTregs further support that both 338 populations contribute to the restoration of a more balanced and complete disease-339 relevant amTreg repertoire.

340 Treg specificity to diabetes-related antigens

The existence of public databases containing TCRs with known peptide specificities allowed us to investigate the presence of antigen-specific sequences in our repertoires. Diabetes-related CDR3s identified from the database were overrepresented in IL-2-treated NOD Tregs and most connected in LD=1 networks, as shown by their high number of neighbors. Linking the CDR3 similarity networks to annotated TCR datasets was previously described by Madi et al., and showed that CDR3s with similar specificity tend to cluster together (*34*). This indicates that diabetes-specific CDR3s could have core motifs engaged in pancreatic antigen recognition, and shows the potential of such a tool in identifying novel pathogenic TCRs. Indeed, repertoire analysis of islet-infiltrating T cells revealed an accumulation of TCRs that were reactive in vitro to uncharacterized autoantigens, distinct from the well-known glutamic acid decarboxylase and insulin antigens (*13*).

These observations highlight a relationship between the specific expansion of pancreatic antigen-related TCRs and the prevention of diabetes post IL-2 treatment.

355 Contribution of I-A^{g7} to NOD pathophysiology

356 It was hypothesized that diabetes development in NOD mice is associated with the I-A^{g7} molecule that they express. Co-expression with a different type of MHC or 357 mutations within the I- A^{g7} molecule were shown to prevent insulitis and diabetes (4, 40). 358 359 On the other hand, substitution of non-MHC regions from the C57BL/10 into the NOD strain was sufficient to prevent insulitis or diabetes, despite their expression of the I-A^{g7} 360 361 molecule (41). Our studies highlight the importance of non-MHC genes in diabetes onset 362 in the NOD mouse model. Indeed, we report here that IL-2 administration to pre-diabetic 363 NOD mice, previously shown to prevent the disease outcome, improves amTreg fitness. 364 This would argue that NOD Treg repertoires have the full potential to control 365 autoimmune responses, but fail to do so because an IL-2 deficiency impairs the amTreg 366 repertoire that can control islet autoreactivity.

367 However, our results do not exclude a potential enrichment of autoreactive T cells in the 368 NOD mice repertoire that would take the lead in the periphery where Tregs fail to 369 expand. In this regard, NOD mice have an overrepresentation of CDR3 β sequences

carrying hydrophobic amino acid doublets at positions 6 and 7 that have been shown to
confer high self-reactivity (42). Further studies of the TCR repertoire selection process in
the thymus of NOD mice should help address this important issue.

373 Altogether, our results reveal a link between a reduced expansion of clonotypes within 374 the activated Treg TCR repertoire and the development of an autoimmune disease.-IL-2 375 treatment not only activates Tregs, but also restores a repertoire of TCRs with relevant 376 specificities. Thus, our work indicates that fit amTregs are key to protection from 377 autoimmune diseases and highlights the value of studying these cells separately from the 378 whole Treg population. Importantly, amTreg repertoire abnormalities and restoration are 379 detected in the spleen, which affords a readout that is more representative of the 380 circulation than pancreatic lymph nodes and thus has a translational value. Our results 381 should guide further studies to elucidate the dynamics of pancreatic antigen-specific 382 amTregs in diabetic versus non-diabetic NOD mice, including in mice outside of a 383 pathogen-free environment, and identify TCR-based biomarkers of diabetes.

385 Acknowledgments

We thank F. Jebbawi and L. Barientos for their help in sample collection and cell sorting,
M. Mendez and N. Papaya for their help in RNA extraction and library preparations, and
K. El Soufi for his help in network analyses. We thank the staff of the animal care facility
for their excellent handling of mice. We also thank the UMR 8199 LIGAN-PM
Genomics platform (Lille, France) which belongs to the 'Federation de Recherche' 3508

392 supported by the ANR Equipex 2010 session, for performing the sequencing of our393 libraries.

Labex EGID (European Genomics Institute for Diabetes; ANR-10-LABX-46) and was

394 Funding

391

This work was funded by the TRiPoD ERC-Advanced EU (No. 322856) and RHU iMAP
(ANR-16-RHUS-0001) grants to DK, with additional support from the Sorbonne
Université, INSERM and AP-HP. ILTOO pharma supported HPP.

398 Author contributions

399 VM, GF, PB, VQ, GC, FB, BG, P-GR and EM-F performed the experiments. VM 400 analyzed the data, with contributions from all authors. VM and HPP performed the 401 statistical analyses. VM, EM-F, AS and DK conceived the experiments. VM, AS, EM-F 402 and DK wrote the manuscript, with input from all authors. DK conceptualized and 403 supervised the study and is the guarantor for the contents of the article.

404 **Duality of interest**

405 DK is an investor of a patent related to the use of IL-2 in the treatment of autoimmune 406 diseases, owned by his public institution and licensed to ILTOO pharma, in which DK

407 has interests. The other authors declare no competing financial interests.

409 **References**

410 1. J. Verdaguer, D. Schmidt, A. Amrani, B. Anderson, N. Averill, P. Santamaria,
411 Spontaneous autoimmune diabetes in monoclonal T cell nonobese diabetic mice. *J. Exp.*412 *Med.* 186, 1663–1676 (1997).

- 2. Y.-G. Chen, C. E. Mathews, J. P. Driver, The Role of NOD Mice in Type 1 Diabetes
 Research: Lessons from the Past and Recommendations for the Future. *Front.*
- 415 *Endocrinol.* **9**, 51 (2018).

3. O. Kanagawa, B. A. Vaupel, G. Xu, E. R. Unanue, J. D. Katz, Thymic positive
selection and peripheral activation of islet antigen-specific T cells: separation of two
diabetogenic steps by an I-A(g7) class II MHC beta-chain mutant. *J. Immunol.* 161,
4489–4492 (1998).

420 4. T. Lund, L. O'Reilly, P. Hutchings, O. Kanagawa, E. Simpson, R. Gravely, P. 421 Chandler, J. Dyson, J. K. Picard, A. Edwards, D. Kioussis, A. Cooke, Prevention of 422 insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding 423 modified I-A β-chain or normal I-E α -chain. *Nature*. **345**, 727–729 (1990).

5. D. Klatzmann, A. K. Abbas, The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. *Nature Reviews Immunology*. **15**, 283–294 (2015).

6. S. A. Long, K. Cerosaletti, P. L. Bollyky, M. Tatum, H. Shilling, S. Zhang, Z.-Y.
Zhang, C. Pihoker, S. Sanda, C. Greenbaum, J. H. Buckner, Defects in IL-2R signaling
contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+)
regulatory T-cells of type 1 diabetic subjects. *Diabetes*. 59, 407–415 (2010).

- 431 7. E. Sgouroudis, A. Albanese, C. A. Piccirillo, Impact of protective IL-2 allelic variants
 432 on CD4+ Foxp3+ regulatory T cell function in situ and resistance to autoimmune diabetes
 433 in NOD mice. *J. Immunol.* 181, 6283–6292 (2008).
- 8. C. J. Dwyer, A. L. Bayer, C. Fotino, L. Yu, C. Cabello-Kindelan, N. C. Ward, K. H.
 Toomer, Z. Chen, T. R. Malek, Altered homeostasis and development of regulatory T cell
 subsets represent an IL-2R-dependent risk for diabetes in NOD mice. *Sci Signal.* 10
 (2017), doi:10.1126/scisignal.aam9563.
- 9. G. Churlaud, V. Jimenez, J. Ruberte, M. Amadoudji Zin, G. Fourcade, G. Gottrand, E.
 Casana, B. Lambrecht, B. Bellier, E. Piaggio, F. Bosch, D. Klatzmann, Sustained
 stimulation and expansion of Tregs by IL2 control autoimmunity without impairing
 immune responses to infection, vaccination and cancer. *Clinical Immunology*. 151, 114–
 126 (2014).
- 443 10. M. Rosenzwajg, G. Churlaud, R. Mallone, A. Six, N. Dérian, W. Chaara, R.
 444 Lorenzon, S. A. Long, J. H. Buckner, G. Afonso, H.-P. Pham, A. Hartemann, A. Yu, A.
 445 Pugliese, T. R. Malek, D. Klatzmann, Low-dose interleukin-2 fosters a dose-dependent

- regulatory T cell tuned milieu in T1D patients. *Journal of Autoimmunity*. 58, 48–58(2015).
- 11. I. Marrero, A. Vong, Y. Dai, J. D. Davies, T cell populations in the pancreatic lymph
 node naturally and consistently expand and contract in NOD mice as disease progresses. *Molecular Immunology*. 52, 9–18 (2012).
- 12. L. Li, Q. He, A. Garland, Z. Yi, L. T. Aybar, T. B. Kepler, J. A. Frelinger, B. Wang,
 R. Tisch, Cell-Specific CD4+ T Cell Clonotypes in Peripheral Blood and the Pancreatic
 Islets Are Distinct. *The Journal of Immunology*. 183, 7585–7591 (2009).
- 454 13. F. J. Baker, M. Lee, Y. -h. Chien, M. M. Davis, Restricted islet-cell reactive T cell
 455 repertoire of early pancreatic islet infiltrates in NOD mice. *Proceedings of the National*456 *Academy of Sciences.* 99, 9374–9379 (2002).
- 457 14. Nakano, T cell receptor V gene usage of islet beta cell-reactive T cells is not
 458 restricted in non-obese diabetic mice. *Journal of Experimental Medicine*. **173**, 1091–1097
 459 (1991).
- 460 15. I. Marrero, D. E. Hamm, J. D. Davies, High-Throughput Sequencing of Islet-461 Infiltrating Memory CD4+ T Cells Reveals a Similar Pattern of TCR V β Usage in 462 Prediabetic and Diabetic NOD Mice. *PLoS ONE*. **8**, e76546 (2013).
- 463 16. I. Marrero, C. Aguilera, D. E. Hamm, A. Quinn, V. Kumar, High-throughput 464 sequencing reveals restricted TCR Vβ usage and public TCRβ clonotypes among 465 pancreatic lymph node memory CD4 + T cells and their involvement in autoimmune 466 diabetes. *Molecular Immunology*. **74**, 82–95 (2016).
- 17. H. R. Seay, E. Yusko, S. J. Rothweiler, L. Zhang, A. L. Posgai, M. CampbellThompson, M. Vignali, R. O. Emerson, J. S. Kaddis, D. Ko, M. Nakayama, M. J. Smith,
 J. C. Cambier, A. Pugliese, M. A. Atkinson, H. S. Robins, T. M. Brusko, Tissue
 distribution and clonal diversity of the T and B cell repertoire in type 1 diabetes
 (2016),doi:10.1172/jci.insight.88242.
- 472 18. C. Ferreira, Y. Singh, A. L. Furmanski, F. S. Wong, O. A. Garden, J. Dyson, Non473 obese diabetic mice select a low-diversity repertoire of natural regulatory T cells.
 474 *Proceedings of the National Academy of Sciences*. 106, 8320–8325 (2009).
- 475 19. J. Kern, R. Drutel, S. Leanhart, M. Bogacz, R. Pacholczyk, Reduction of T Cell
 476 Receptor Diversity in NOD Mice Prevents Development of Type 1 Diabetes but Not
 477 Sjögren's Syndrome. *PLoS ONE*. 9, e112467 (2014).
- 20. P.-G. Ritvo, A. Saadawi, P. Barennes, V. Quiniou, W. Chaara, K. El Soufi, B.
 Bonnet, A. Six, M. Shugay, E. Mariotti-Ferrandiz, D. Klatzmann, High-resolution
 repertoire analysis reveals a major bystander activation of Tfh and Tfr cells. *Proc Natl Acad Sci USA*. 115, 9604–9609 (2018).

482 21. S. Fisson, G. Darrasse-Jèze, E. Litvinova, F. Septier, D. Klatzmann, R. Liblau, B. L.
483 Salomon, Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the
484 steady state. *J. Exp. Med.* **198**, 737–746 (2003).

485 22. A.-S. Bergot, W. Chaara, E. Ruggiero, E. Mariotti-Ferrandiz, S. Dulauroy, M.
486 Schmidt, C. von Kalle, A. Six, D. Klatzmann, TCR sequences and tissue distribution
487 discriminate the subsets of naïve and activated/memory Treg cells in mice: Molecular
488 immunology. *European Journal of Immunology*. 45, 1524–1534 (2015).

- 489 23. P. Barennes, V. Quiniou, M. Shugay, E. S. Egorov, A. N. Davydov, D. M. Chudakov,
- 490 I. Uddin, M. Ismail, T. Oakes, B. Chain, A. Eugster, K. Kashofer, P. P. Rainer, S. Darko,
- A. Ransier, D. C. Douek, D. Klatzmann, E. Mariotti-Ferrandiz, Benchmarking of T cell
 receptor repertoire profiling methods reveals large systematic biases. *Nat Biotechnol*(2020)
- 494 24. D. A. Bolotin, S. Poslavsky, I. Mitrophanov, M. Shugay, I. Z. Mamedov, E. V.
 495 Putintseva, D. M. Chudakov, MiXCR: software for comprehensive adaptive immunity
 496 profiling. *Nature Methods.* 12, 380–381 (2015).
- 497 25. P. Jaccard, Étude comparative de la distribution florale dans une portion des Alpes et
 498 du Jura. *Imprimerie Corbaz & Comp.* (1901)
- 499 26. R. Kolde, pheatmap (2019).
- 27. R. Alfred, On measures of entropy and information. In: *Proceedings of the Fourth Berkeley Symposium on Mathematical Statistics and Probability* (1961), pp. 547–61.
- 502 28. H. Wickham, D. Navarro, T. Lin Pedersen, ggplot2: Elegant Graphics for Data
 503 Analysis (Springer, 2nd edition).
- 29. P.J. van der Loo, Mark, The stringdist Package for ApproximateString Matching. *The R Journal*. Vol. 6/1, (2020)
- 506 30. G. Csardi, T. Nepusz, The igraph software package for complex network research (2006).
- 508 31. P. Shannon, Cytoscape: A Software Environment for Integrated Models of 509 Biomolecular Interaction Networks. *Genome Research.* **13**, 2498–2504 (2003).
- 510 32. N. Tickotsky, T. Sagiv, J. Prilusky, E. Shifrut, N. Friedman, McPAS-TCR: a 511 manually curated catalogue of pathology-associated T cell receptor sequences. 512 *Bioinformatics*. **33**, 2924–2929 (2017).
- 513 33. Alboukadel, ggpubr R Package: ggplot2-Based Publication Ready Plots (2020)
- 514 34. A. Madi, A. Poran, E. Shifrut, S. Reich-Zeliger, E. Greenstein, I. Zaretsky, T. Arnon,
- 515 F. V. Laethem, A. Singer, J. Lu, P. D. Sun, I. R. Cohen, N. Friedman, T cell receptor
- 516 repertoires of mice and humans are clustered in similarity networks around conserved
- 517 public CDR3 sequences. *eLife*. **6** (2017), doi:10.7554/eLife.22057.

- 518 35. G. Darrasse-Jèze, A.-S. Bergot, A. Durgeau, F. Billiard, B. L. Salomon, J. L. Cohen,
- 519 B. Bellier, K. Podsypanina, D. Klatzmann, Tumor emergence is sensed by self-specific 520 CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in 521 mice. *Journal of Clinical Investigation* (2009)
- 522 36. Y. Elhanati, A. Murugan, C. G. Callan, T. Mora, A. M. Walczak, Quantifying 523 selection in immune receptor repertoires. *Proceedings of the National Academy of* 524 *Sciences.* **111**, 9875–9880 (2014).
- 525 37. G. D. Kitas, M. Salmon, M. Farr, J. S. Gaston, P. A. Bacon, Deficient interleukin 2 526 production in rheumatoid arthritis: association with active disease and systemic 527 complications. *Clin. Exp. Immunol.* **73**, 242–249 (1988).
- 528 38. K. S. Zier, M. M. Leo, R. S. Spielman, L. Baker, Decreased Synthesis of Interleukin-529 2 (IL-2) in Insulin-dependent Diabetes Mellitus. *Diabetes*. **33**, 552–555 (1984).

530 39. V. Thomas-Vaslin, H. K. Altes, R. J. de Boer, D. Klatzmann, Comprehensive 531 Assessment and Mathematical Modeling of T Cell Population Dynamics and 532 Homeostasis. *J Immunol.* **180**, 2240–2250 (2008).

40. L. Gioia, M. Holt, A. Costanzo, S. Sharma, B. Abe, L. Kain, M. Nakayama, X. Wan, A. Su, C. Mathews, Y.-G. Chen, E. Unanue, L. Teyton, Position β 57 of I-A ^{g7} controls early anti-insulin responses in NOD mice, linking an MHC susceptibility allele to type 1 diabetes onset. *Sci. Immunol.* **4**, eaaw6329 (2019).

537 41. D. V. Serreze, M. Bridgett, H. D. Chapman, E. Chen, S. D. Richard, E. H. Leiter, 538 Subcongenic Analysis of the Idd13 Locus in NOD/Lt Mice: Evidence for Several 539 Susceptibility Genes Including a Possible Diabetogenic Role for β2-Microglobulin. *The* 540 *Journal of Immunology*. **160**, 1472–1478 (1998).

42. B. D. Stadinski, K. Shekhar, I. Gómez-Touriño, J. Jung, K. Sasaki, A. K. Sewell, M.
Peakman, A. K. Chakraborty, E. S. Huseby, Hydrophobic CDR3 residues promote the
development of self-reactive T cells. *Nature Immunology*. **17**, 946–955 (2016).

545 Figures



Figure 1. B6 and NOD mice express different TCR repertoires. (A) PCA biplot for
TRBVBJ usage of all B6 (dots) and NOD (triangles) samples. Cell populations are
identified based on their colors. (B) Heatmap of the pairwise Jaccard distances calculated
at the clonotype level. Scores range between 0 (complete similarity) and 1 (no similarity).
The hierarchical clustering was performed using Ward's method.





555 Figure 2. Increased diversity of NOD Teffs and amTregs compared to B6. (A) Renyi 556 profiles for nTregs (yellow), CD4 Teffs (green) and amTregs (blue) in B6 and NOD 557 mice. Points represent the mean of all six mice and shaded areas represent the standard 558 error. (B) Renyi values were compared between B6 and NOD mice within each cell 559 population at alpha = 0 and alpha = 8. (C) Mean cumulative percentage of the 100 most 560 predominant clonotypes of the six mice for each cell population. (D) Percentage of the 561 top 100 clonotypes within the three cell populations in B6 (upper plot) and in NOD 562 (lower plot) backgrounds. Each blue line and its thickness represent a unique clonotype 563 and its occurrence, grey "bars" are the stacking of slim grey lines representing rare clonotypes. (B, C) n=6, ns P > 0.05, * P ≤ 0.05 , ** P ≤ 0.01 , Wilcoxon test with Holm's 564 correction. 565



567 568

Figure 3. Similarity structure of nTreg, Teff and amTreg CDR3 repertoires. (A) For

569 each cell population, the most frequent 1000 CDR3s across all mice were identified based 570 on their mean frequency and used to construct networks based on the Levenshtein 571 distance: CDR3 sequences (nodes) with amino acid difference one 572 (insertion/deletion/substitution) are connected by an edge. One network was constructed 573 per cell population and mouse background. (B) CDR3 frequency comparison between B6 574 and NOD mice for each cell subset. (C) Comparison of the-clustering coefficient, which 575 quantifies the degree to which neighbor nodes tend to cluster together, between B6 and

576 NOD mice in each cell subset. CDR3s with no connections are excluded. (**B**, **C**) Each dot 577 represents a CDR3 and boxplots represent the median, first and third quartiles. ns P > 578 0.05, *** P ≤ 0.001 , **** P ≤ 0.0001 , Wilcoxon test with Holm's correction.



Figure 4. IL-2 induces Treg clonotype expansions. (**A**) Experimental scheme. (**B**) Box plots show the percentage of T cells in each B6 (orange), NOD (purple) and IL-2–treated NOD (yellow) mice (n=6 per background). (**C, left plot**) The abundance (in %) of expanded clonotypes for each sample (each column represents a single sample) within the three populations and mouse backgrounds. Expanded clonotypes were identified as the ones with counts greater than Q3+1.5xIQR according to a fitted negative binomial

586 distribution. (C, right plot) Probability density plot based on the mean expanded 587 clonotype distribution between the three mouse conditions for each cell subset. Colored 588 dashed lines represent the mode of each curve.





593

Figure 5. IL-2 preferentially expands clonotypes with a diabetes-related specificity. 591 (A) The proportion of CDR3s specific for cancer, EAE, SLE and diabetes found within 592 the expanded clonotypes of each population (n=6). Box-and-whisker plots show the

median and outliers. (B) CDR3s with a disease-related specificity were connected by

594 LD=1 to the pool of amTreg and nTreg CDR3s identified across the six IL-2 treated 595 NOD mice. The degree of connectivity, i.e the number of LD=1 edges connecting a given 596 node, of disease-specific CDR3s is plotted (n=52 in cancer, n=50 in EAE, n=49 in SLE 597 and n=52 in T1D). (A, B) Wilcoxon test was performed with the T1D group as a reference: ns p > 0.05, * P ≤ 0.05 , ** P ≤ 0.01 and *** P ≤ 0.001 . (C) Graphical 598 representation of the LD=1 networks in NOD AAV-IL-2 treated nTregs and amTregs. 599 600 Unconnected sequences are not shown. Identical sequences found in the database and 601 samples from IL-2 treated mice are shown in red, their neighbors in blue as well as 602 diabetes-related sequences from the database.